Explore more publications!

Press Releases

U.S. Shrimpers Respond to the Supreme Court Ruling on Tariffs
ThinkCareBelieve: Week 57 of the Trump 2.0 Administration
QuantumForce Inc. Launches Guruchats, a Secure Non-Recordable Video Platform for Open Dialogue in the U.S.A.
Perfumes Capital Makes a Glamorous U.S. Debut with a Luxury Launch in Miami
Korean-American Pharmacist to Launch Glowpatch Relief, Globally Proven Menstrual Wellness Device, in U.S. Market
U.S. Economy Misses 3 Percent Forecast in Q4 of 2025

U.S. Economy Misses 3 Percent Forecast in Q4 of 2025

U.S. Supreme Court Rules Against Trump's Global Tariffs

U.S. Supreme Court Rules Against Trump's Global Tariffs

U.S. Economy Expands Just 1.4 Percent in Q4 2025

U.S. Economy Expands Just 1.4 Percent in Q4 2025

U.S. Posts USD70.3B Trade Deficit in December

U.S. Posts USD70.3B Trade Deficit in December

U.S. Withdraws Troops from Qatar, Bahrain

U.S. Withdraws Troops from Qatar, Bahrain

Planet3 and Theaus Global Announce Planetary Capital - A $1B Asset-Backed Portfolio for the $1T Carbon Economy
Councilmember Will Jawando’s Statement on U.S. Supreme Court Ruling Striking Down Trump Tariffs

Councilmember Will Jawando’s Statement on U.S. Supreme Court Ruling Striking Down Trump Tariffs

Genesis Signs & Graphics Highlights Acrylic Sign Trends for Retail and Small Business Owners: What’s In and What’s Out
Leanafy Announces Major 2025 Milestones, North American Expansion, IWLA Membership, and 2026 Industry Engagement
U.S. Global Investors Reports 12% Sequential Growth in Assets Under Management in Q2 of Fiscal 2026
Trump Signs 10 Percent Tariff Order Hours After IEEPA Ruling

Trump Signs 10 Percent Tariff Order Hours After IEEPA Ruling

Trump Weighs Limited Military Strike Against Iran

Trump Weighs Limited Military Strike Against Iran

Trump Imposes Global Tariff on All Imports

Trump Imposes Global Tariff on All Imports

Trump Cancels Key Tariffs After Supreme Court Ruling

Trump Cancels Key Tariffs After Supreme Court Ruling

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions